107 related articles for article (PubMed ID: 9427798)
1. Assessment of early epirubicin cardiotoxicity in women with breast cancer.
Sobić-Saranović D; Pavlović S; Susnjar S; Neskovi c-Konstantinović Z; Jelić S
Anticancer Res; 1997; 17(5B):3889-91. PubMed ID: 9427798
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of left ventricular function in patients with mammary carcinoma after treatment with epidoxorubicin using a high-dose, short-term protocol].
D'Alto M; Maurea S; Basso A; Polverino W; Bianchi U; Bonelli A; Silvestro P; Salvatore M; Chiariello M
Cardiologia; 1997 Jun; 42(6):611-8. PubMed ID: 9289377
[TBL] [Abstract][Full Text] [Related]
3. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
Mercuro G; Cadeddu C; Piras A; Dessì M; Madeddu C; Deidda M; Serpe R; Massa E; Mantovani G
Oncologist; 2007 Sep; 12(9):1124-33. PubMed ID: 17914082
[TBL] [Abstract][Full Text] [Related]
4. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
Florescu M; Magda LS; Enescu OA; Jinga D; Vinereanu D
J Am Soc Echocardiogr; 2014 Jan; 27(1):83-92. PubMed ID: 24268372
[TBL] [Abstract][Full Text] [Related]
5. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
6. Can the epirubicin cardiotoxicity in cancer patients be prevented by angiotensin converting enzyme inhibitors?
Radulescu D; Buzdugan E; Ciuleanu TE; Todor N; Stoicescu L
J BUON; 2013; 18(4):1052-7. PubMed ID: 24344038
[TBL] [Abstract][Full Text] [Related]
7. Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography.
Cottin Y; Touzery C; Dalloz F; Coudert B; Toubeau M; Riedinger A; Louis P; Wolf JE; Brunotte F
Clin Cardiol; 1998 Sep; 21(9):665-70. PubMed ID: 9755384
[TBL] [Abstract][Full Text] [Related]
8. Left ventricular diastolic performance in breast cancer survivors treated with anthracyclines.
Radulescu D; Pripon S; Radulescu LI; Duncea C
Acta Cardiol; 2008 Feb; 63(1):27-32. PubMed ID: 18372577
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography.
Pichon MF; Cvitkovic F; Hacene K; Delaunay J; Lokiec F; Collignon MA; Pecking AP
In Vivo; 2005; 19(3):567-76. PubMed ID: 15875778
[TBL] [Abstract][Full Text] [Related]
10. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
11. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.
Cochet A; Quilichini G; Dygai-Cochet I; Touzery C; Toubeau M; Berriolo-Riedinger A; Coudert B; Cottin Y; Fumoleau P; Brunotte F
Breast Cancer Res Treat; 2011 Dec; 130(3):845-54. PubMed ID: 21918836
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
[TBL] [Abstract][Full Text] [Related]
13. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular diastolic function assessed with cardiovascular magnetic resonance imaging and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy.
Małek LA; Chojnowska L; Kłopotowski M; Misko J; Dabrowski M; Kuśmierczyk-Droszcz B; Maczyńska R; Piotrowicz E; Ruzyłło W
Kardiol Pol; 2009 Jan; 67(1):1-6; discussion 7-8. PubMed ID: 19253184
[TBL] [Abstract][Full Text] [Related]
15. [Disproportionate shortening of left ventricular diastolic duration in patients with dilated cardiomyopathy].
Plehn G; Vormbrock J; Zühlke C; Christ M; Perings C; Perings S; Trappe HJ; Meissner A
Med Klin (Munich); 2007 Sep; 102(9):707-13. PubMed ID: 17879008
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI.
Nagy AC; Tolnay E; Nagykálnai T; Forster T
Neoplasma; 2006; 53(6):511-7. PubMed ID: 17167721
[TBL] [Abstract][Full Text] [Related]
17. Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline? A 1-year follow-up study of women.
Cottin Y; Touzery C; Coudert B; Richebourg S; Cohen M; Toubeau M; Louis P; Wolf JE; Brunotte F
Eur J Nucl Med; 1996 May; 23(5):511-6. PubMed ID: 8698054
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.
Meinardi MT; van Veldhuisen DJ; Gietema JA; Dolsma WV; Boomsma F; van den Berg MP; Volkers C; Haaksma J; de Vries EG; Sleijfer DT; van der Graaf WT
J Clin Oncol; 2001 May; 19(10):2746-53. PubMed ID: 11352968
[TBL] [Abstract][Full Text] [Related]
20. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
